Syros Pharmaceuticals Incorporated (NASDAQ:SYRS) had an increase of 21.56% in short interest. SYRS’s SI was 1.43 million shares in February as released by FINRA. Its up 21.56% from 1.17M shares previously. With 214,800 avg volume, 7 days are for Syros Pharmaceuticals Incorporated (NASDAQ:SYRS)’s short sellers to cover SYRS’s short positions. The SI to Syros Pharmaceuticals Incorporated’s float is 20.09%. The stock decreased 3.02% or $0.3 during the last trading session, reaching $9.63. About 676,490 shares traded or 66.93% up from the average. Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) has 0.00% since February 11, 2017 and is . It has underperformed by 16.70% the S&P500.
Analysts expect TriplePoint Venture Growth BDC Corp. (NYSE:TPVG) to report $0.32 EPS on March, 12.They anticipate $0.02 EPS change or 6.67% from last quarter’s $0.3 EPS. TPVG’s profit would be $5.67 million giving it 9.23 P/E if the $0.32 EPS is correct. After having $0.27 EPS previously, TriplePoint Venture Growth BDC Corp.’s analysts see 18.52% EPS growth. The stock increased 0.60% or $0.07 during the last trading session, reaching $11.82. About 53,186 shares traded. TriplePoint Venture Growth BDC Corp. (NYSE:TPVG) has risen 28.59% since February 11, 2017 and is uptrending. It has outperformed by 11.89% the S&P500.
Among 2 analysts covering TriplePoint Venture Growth BDC Corp. (NYSE:TPVG), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. TriplePoint Venture Growth BDC Corp. had 6 analyst reports since June 29, 2016 according to SRatingsIntel. The stock has “Neutral” rating by Compass Point on Thursday, August 25. The firm has “Hold” rating given on Tuesday, August 29 by Compass Point. The rating was initiated by Compass Point on Wednesday, June 29 with “Buy”. The firm has “Buy” rating by Compass Point given on Tuesday, November 28. Compass Point upgraded the shares of TPVG in report on Thursday, September 22 to “Buy” rating. The stock of TriplePoint Venture Growth BDC Corp. (NYSE:TPVG) earned “Buy” rating by Ladenburg Thalmann on Monday, May 2.
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing treatments for cancer and immune-mediated diseases, and building a pipeline of gene control medicines. The company has market cap of $303.74 million. The Company’s lead drug candidates are SY-1425, a selective RARa agonist in a Phase 2 clinical trial for genomically defined subsets of patients with acute myeloid leukemia and myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor with potential in a range of solid tumors and blood cancers. It currently has negative earnings. The firm was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012.